SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03239145
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This research study is studying an investigational combination of drugs as a possible
treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer.
The drugs involved in this study are:
- Pembrolizumab
- AMG386
NCT03239145 Advanced Solid Tumor
2 Interventions
Name: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
Type: Drug
Group Labels: 5 Pembrolizumab + Trebananib Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Renal Cell Carcinoma)
Name: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
Type: Drug
Group Labels: 5 Pembrolizumab + Trebananib Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Renal Cell Carcinoma)
Primary Outcomes
Measure: Dose Limiting Toxicity Time: 2 years
Secondary Outcomes
Measure: Objective Response Rate Time: 2 years
Measure: Progression Free Survival Time: 2 years
Measure: Overall Survival Time: 2 years
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment
There are 2 SNPs
SNPs
Melanoma
patients with BRAF V600E or V600K mutation-positive melanoma who have previously
received a BRAF inhibitor with or without a MEK inhibitor) are eligible. --- V600E ---